Chemocentryx Inc., of Mountain View, Calif., reported that patients taking a higher dose of vercirnon (CCX282-B, Traficet-EN) for Crohn's disease during the phase III SHEILD-4 study experienced improved response and remission rates when taking a 500-mg dose of the drug twice-daily instead of just once-daily.